M C Thomas1, M E Cooper, K Rossing, H H Parving. 1. Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, VIC, Australia. mthomas@baker.edu.au
Abstract
BACKGROUND: Anaemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment. In tertiary clinics, at least one outpatient in five with diabetes has anaemia, for whom it constitutes a significant additional burden. DISCUSSION: Anaemia is associated with an increased risk of diabetic complications including nephropathy, retinopathy and macrovascular disease. Anaemia may also be significant in determining the outcome of heart failure and hypoxia-induced organ damage in diabetes. While several factors contribute to the increased prevalence of anaemia in diabetes, the failure of the kidney to increase erythropoietin in response to falling haemoglobin appears to be the dominant factor. Although there is a clear rationale for correcting anaemia in people with diabetes, it remains to be established whether this will lead to improved outcomes. Moreover, the balance of risks, costs, and benefits remains to be established in patients with diabetes. The Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is a randomised controlled trial designed to determine the impact of anaemia correction on mortality and non-fatal cardiovascular events in patients with type 2 diabetes and stage 3-4 nephropathy. CONCLUSION: It is anticipated that TREAT will help to define the optimal approach to the management of anaemia in diabetes.
BACKGROUND:Anaemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment. In tertiary clinics, at least one outpatient in five with diabetes has anaemia, for whom it constitutes a significant additional burden. DISCUSSION: Anaemia is associated with an increased risk of diabetic complications including nephropathy, retinopathy and macrovascular disease. Anaemia may also be significant in determining the outcome of heart failure and hypoxia-induced organ damage in diabetes. While several factors contribute to the increased prevalence of anaemia in diabetes, the failure of the kidney to increase erythropoietin in response to falling haemoglobin appears to be the dominant factor. Although there is a clear rationale for correcting anaemia in people with diabetes, it remains to be established whether this will lead to improved outcomes. Moreover, the balance of risks, costs, and benefits remains to be established in patients with diabetes. The Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is a randomised controlled trial designed to determine the impact of anaemia correction on mortality and non-fatal cardiovascular events in patients with type 2 diabetes and stage 3-4 nephropathy. CONCLUSION: It is anticipated that TREAT will help to define the optimal approach to the management of anaemia in diabetes.
Authors: P L Brito; P Fioretto; K Drummond; Y Kim; M W Steffes; J M Basgen; S Sisson-Ross; M Mauer Journal: Kidney Int Date: 1998-03 Impact factor: 10.612
Authors: H Yokoyama; O Tomonaga; M Hirayama; A Ishii; M Takeda; T Babazono; U Ujihara; C Takahashi; Y Omori Journal: Diabetologia Date: 1997-04 Impact factor: 10.122
Authors: William McClellan; Stephen L Aronoff; W Kline Bolton; Sally Hood; Daniel L Lorber; K Linda Tang; Thomas F Tse; Brian Wasserman; Marc Leiserowitz Journal: Curr Med Res Opin Date: 2004-09 Impact factor: 2.580
Authors: Renato M B Roman; Peter I Lobo; Ronald P Taylor; David A Goodkin; John LaBrecque; Kathy L Powers; W Kline Bolton Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: Uğur Fırat; Savaş Kaya; Abdullah Cim; Hüseyin Büyükbayram; Osman Gökalp; Mehmet Sinan Dal; Mehmet Numan Tamer Journal: Exp Diabetes Res Date: 2012-04-26
Authors: Angelo Avogaro; Mattia Albiero; Lisa Menegazzo; Saula de Kreutzenberg; Gian Paolo Fadini Journal: Diabetes Care Date: 2011-05 Impact factor: 19.112
Authors: Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2014-12-08